12,372 trials
Head and Neck Cancer
Primary: Objective Response Rate (ORR) of Pembrolizumab + Epacadostat, Pembrolizumab Monotherapy and the EXTREME Regimen — 31.4; 21.1; 34.3 percentage of participants
Renal Cell Carcinoma (RCC)
Primary: Objective Response Rate (ORR) of Pembrolizumab + Epacadostat Versus Standard of Care (SOC) — 1.6; 0.0; 29.7; 29.2 percentage of participants
Cerebrospinal Fluid Leak
Primary: Number of Participants With No CSF Leak During and After Surgery — 76; 87 Participants
Ankylosing Spondylitis
Primary: Assessment of SpondyloArthritis International Society 20 Response (ASAS20) — 21 participants
Renal Insufficiency, Chronic
Primary: Number of Participants With a Urine Albumin Excretion Decrease of 20% or More — 19; 13 Participants — p=0.257
Bone Metastases in Men With Hormone-Refractory Prostate Cancer · Bone Metastases in Subjects With Advanced Breast Cancer
Primary: Number of Participants With Adverse Events — 98; 45; 28; 22 Participants
Obstructive Sleep Apnea
Primary: Change in the Maintenance of Wakefulness Test (MWT) — -0.96; -12.11 minutes
Hypercholesterolaemia
Primary: Percentage of SYDNEY-Associated Product Technical Complaints (PTCs) (Overall) at the Unsupervised Injections: Single-Arm Period — 0.5 percentage of PTCs
Gastroenteritis
Primary: Number of Participants With Modified Vesikari Scale Score >=9 — 55; 60 Participants — p=0.83
Anogenital Human Papilloma Virus Infection · Condyloma Acuminata
Primary: Percentage of Participants With Seroconversion for HPV Types 6, 11, 16, and 18 — 94.9; 99.0; 99.0; 99.0 Percentage of Participants
Stroke · Secondary Prevention
Primary: Adjudicated Recurrent Stroke — 4.09; 4.80 Annualised event rate (%/ year) — p=0.1028
Rhinitis, Allergic, Seasonal
Primary: Change From Baseline in Total Nasal Symptom Score Averaged Over Day 1 Through Day 15 (Based on Participant Diaries) — -2.8; -3.4; -0.9 Score on a scale — p=<0.01
Hemophilia
Primary: Percentage of Surgical or Other Invasive Procedures Defined as "Good" or "Excellent" Response to LR769 Treatment as Assessed by the Investigator, Based on the Totality…
Opioid-Induced Constipation
Primary: Average Percentage of Dosing Days That Resulted in Rescue-Free Bowel Movements (RFBMs) Within 4 Hours of Dosing During Weeks 1 to 4 — 21.05; 24.64; 27.40; 18.18…
Drug-specific Antibodies · Diabetes Mellitus
Primary: Percentage of Participants With Treatment-emergent Anti-Drug Antibody (ADA) — 0; 2.0 percentage of participants